^
Association details:
| Biomarker: | HR-positive + PIK3CA wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer
Excerpt:
All HER2-positive patients received either trastuzumab or lapatinib or the combination plus anthracycline-taxane chemotherapy....In the 291 hormone receptor (HR)–positive tumors, pCR rate was 11.3% with a PIK3CA mutation compared with 27.5% with PIK3CA wild-type (OR, 0.34; 95% CI, 0.15 to 0.78; P .011)....In patients with PIK3CA mutation, the pCR rates were 16%, 24.3%, and 17.4% with lapatinib, trastuzumab, and the combination, respectively (P=0.654) and in the wild-type group, they were 18.2%, 33.%, and 37.1%, respectively (P .017)....There were higher pCR rates in PIK3CA wild-type tumors, especially in the HR-positive/HER2-positive cohorts (Fig 3).
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2014.55.7876
